NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Clopidogrel Prevention of Early Arteriovenous (AV) Fistula Thrombosis

Phase 3

Completed

Conditions: Kidney Failure
Hemodialysis Fistula Thrombosis

Interventions: Drug: Clopidogrel
Drug: Placebo

First Posted Date: 2017-09-21

Last Posted Date: 2025-05-30

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 877

Registration Number: NCT03289520

Locations: 🇺🇸
Maine Medical Center, Portland, Maine, United States
🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
🇺🇸
Boston University Medical Center, Boston, Massachusetts, United States

and more 6 locations

Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia

Phase 2

Active, not recruiting

Conditions: Essential Thrombocythemia
Atypical Chronic Myeloid Leukemia
Myelodysplastic/Myeloproliferative Neoplasm
Myelofibrosis
Acute Myeloid Leukemia
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Chronic Myelomonocytic Leukemia
Polycythemia Vera
Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia

Interventions: Drug: Carboplatin
Drug: Topotecan
Drug: Topotecan Hydrochloride
Drug: Veliparib

First Posted Date: 2017-09-21

Last Posted Date: 2025-01-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 25

Registration Number: NCT03289910

Locations: 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
USC Norris Oncology/Hematology-Newport Beach, Newport Beach, California, United States
🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

and more 3 locations

Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2

Phase 2

Active, not recruiting

Conditions: Locally Advanced Clear Cell Renal Cell Carcinoma
Metastatic Malignant Solid Neoplasm
Locally Advanced Malignant Solid Neoplasm
Stage IV Renal Cell Cancer AJCC v8
Metastatic Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma
Stage III Renal Cell Cancer AJCC v8

Interventions: Drug: Adavosertib

First Posted Date: 2017-09-15

Last Posted Date: 2025-02-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT03284385

Locations: 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸
Siteman Cancer Center at Christian Hospital, Saint Louis, Missouri, United States
🇺🇸
University of Kansas Cancer Center, Kansas City, Kansas, United States

and more 26 locations

Defined Green Tea Catechin Extract in Preventing Liver Cancer in Participants With Cirrhosis

Phase 1

Active, not recruiting

Conditions: Cirrhosis

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Defined Green Tea Catechin Extract
Other: Laboratory Biomarker Analysis
Procedure: Magnetic Resonance Imaging
Other: Pharmacological Study
Other: Questionnaire Administration
Procedure: Ultrasound

First Posted Date: 2017-09-12

Last Posted Date: 2024-08-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 14

Registration Number: NCT03278925

Locations: 🇵🇷
University of Puerto Rico, San Juan, Puerto Rico
🇺🇸
MedStar Georgetown University Hospital, Washington, District of Columbia, United States

Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

Phase 2

Active, not recruiting

Conditions: Grade 2 Follicular Lymphoma
Grade 3a Follicular Lymphoma
Recurrent Follicular Lymphoma
Grade 1 Follicular Lymphoma
Refractory Follicular Lymphoma

Interventions: Procedure: Biopsy Procedure
Drug: Bendamustine Hydrochloride
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Echocardiography Test
Procedure: Multigated Acquisition Scan
Drug: Lenalidomide
Drug: Cyclophosphamide
Biological: Obinutuzumab
Drug: Doxorubicin Hydrochloride
Procedure: Positron Emission Tomography
Drug: Umbralisib
Drug: Prednisone
Drug: Vincristine Sulfate

First Posted Date: 2017-09-01

Last Posted Date: 2025-04-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 95

Registration Number: NCT03269669

Locations: 🇺🇸
Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
🇺🇸
Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States
🇺🇸
Alaska Women's Cancer Care, Anchorage, Alaska, United States

and more 428 locations

Sample Collection and Tracking for the Developmental Therapeutics Clinic

Recruiting

Conditions: Neoplasms
Lymphoma

First Posted Date: 2017-09-01

Last Posted Date: 2025-03-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 3000

Registration Number: NCT03269578

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Internet-Based and Self-Reports in Assessing Diet and Physical Activity Within AARP

Completed

Conditions: Healthy Subject

Interventions: Other: Internet-Based Intervention
Device: Monitoring Device
Other: Questionnaire Administration

First Posted Date: 2017-08-31

Last Posted Date: 2020-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1130

Registration Number: NCT03268577

Locations: 🇺🇸
NCI Division of Cancer Control and Population Sciences, Rockville, Maryland, United States

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

Phase 1

Completed

Conditions: Urinary Bladder Neoplasms

Interventions: Drug: Durvalumab
Drug: Vicineum
Drug: Acetaminophen
Drug: Antihistamine
Procedure: Bladder Biopsy
Procedure: TURBT
Procedure: Cystoscopy
Diagnostic Test: Urine cytology
Diagnostic Test: Electrocardiogram
Diagnostic Test: CT
Diagnostic Test: MRI

First Posted Date: 2017-08-23

Last Posted Date: 2025-05-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 15

Registration Number: NCT03258593

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

Phase 2

Active, not recruiting

Conditions: Oropharyngeal Squamous Cell Carcinoma
Stage III Lip and Oral Cavity Cancer AJCC v8
Stage IVA Laryngeal Cancer AJCC v8
Stage IVB Hypopharyngeal Carcinoma AJCC v8
Head and Neck Squamous Cell Carcinoma
Squamous Cell Carcinoma of Unknown Primary
Stage IVA Hypopharyngeal Carcinoma AJCC v8
Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Stage III Hypopharyngeal Carcinoma AJCC v8
Stage IVA Lip and Oral Cavity Cancer AJCC v8

Interventions: Biological: Cetuximab
Biological: Durvalumab
Radiation: Intensity-Modulated Radiation Therapy
Other: Laboratory Biomarker Analysis
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2017-08-23

Last Posted Date: 2025-03-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 196

Registration Number: NCT03258554

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸
Coborn Cancer Center at Saint Cloud Hospital, Saint Cloud, Minnesota, United States
🇺🇸
Springfield Memorial Hospital, Springfield, Illinois, United States

and more 253 locations

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

Phase 2

Recruiting

Conditions: Epstein-Barr Virus Infections
Lymphoproliferative Disorder
Disorders, Lymphoproliferative
Lymphoma

Interventions: Biological: Nivolumab

First Posted Date: 2017-08-23

Last Posted Date: 2025-04-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT03258567

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Home Terms & Conditions Privacy Policy